Eisai To Apply For Japanese Approval For Lunesta Insomnia Drug Within A Year
This article was originally published in PharmAsia News
Executive Summary
Eisai said it intends to apply for Japan approval of U.S.-based Sepracor's Lunestra (eszopiclone) insomnia drug a year from now